• No results found

Allogeneic cellular immunotherapy for chronic B-cell leukemia Hoogendoorn, M.

N/A
N/A
Protected

Academic year: 2021

Share "Allogeneic cellular immunotherapy for chronic B-cell leukemia Hoogendoorn, M."

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Citation

Hoogendoorn, M. (2007, February 15). Allogeneic cellular immunotherapy for chronic B-

cell leukemia. Department of Hematology, Faculty of Medicine, Leiden University Medical

Center (LUMC), Leiden University. Retrieved from https://hdl.handle.net/1887/11408

Version: Corrected Publisher’s Version

License: Licence agreement concerning inclusion of doctoral thesis in the

Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/11408

Note: To cite this publication please use the final published version (if applicable).

(2)

Allogeneic cellular immunotherapy for chronic B-cell leukemia

(3)
(4)

Allogeneic cellular immunotherapy for chronic B-cell leukemia

Proefschrift

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,

op gezag van de Rector Magnificus prof.mr.dr. P.F. van der Heijden, volgens besluit van het College voor Prom oties

te verdedigen op donderdag 15 februari 2007 klokke 16.15 uur

door

Mels Hoogendoorn

geboren te Zoeterm eer in 1965

(5)

Cover: Klaas Koster Lay-out: Bart Nijmeijer Printed by: GildePrint

Financial support for the printing of this thesis was provided by:

Amgen BV, Bristol-Myers Squibb, Bronovo Research Fonds, Novartis BV, Pfizer BV, Roche BV, Schering BV, Ortho Biotec

© M.Hoogendoorn, Suawoude, The Netherlands, 2007

(6)
(7)
(8)

Contents

Chapter 1 9

Introduction

Chapter 2 31

Generation of B-cell chronic lymphocytic leukemia (CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified CLL cells as stimulators: implications for adoptive immunotherapy.

Leukemia. 2004;18:1278-1287

Chapter 3 53

Minor Histocompatibility Antigen (mHag)-specific And B-cell Chronic Lymphocytic Leukemia (CLL)-reactive T Cells Can Be Derived From Matched Sibling Donors Using Transformed CLL Cells As Stimulator Cells.

Submitted

Chapter 4 71

Primary allogeneic T-cell responses against mantle cell lymphoma antigen presenting cells for adoptive immunotherapy after stem cell transplantation.

Clin Cancer Res. 2005;11:5310-5318

Chapter 5 93

Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.

Submitted

Chapter 6 113

Summary and General Discussion

Chapter 7 127

Nederlandse Samenvatting

Nawoord 139

Curriculum Vitae 141

(9)

Referenties

GERELATEERDE DOCUMENTEN

Regarding plasma Ig titers, soluble IgM levels were signi ficantly reduced in both MBL hi (P = 0.03) and CLL-0 (P = 0.008) (Fig. 2e); in addition, MBL hi showed reduced IgG2 and

The proliferative capacity of Vg9Vd2-T cells was similar with allogeneic and autologous moDCs (mean expansion factor 87.00 6 16.46 vs 76.42 6 8.55) and was not impaired in

Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted

The inability of tumor cells to induce autologous T-cell proliferation and cytotoxicity may be caused by insufficient numbers of functional antigen-specific T cells in the

In all three HLA class I-identical donor / patient pairs tested, using these malignant APC as stimulator cells, allogeneic CD8 + T cell lines were generated, recognizing CLL as

(C) Four CD8+ T cell clones out of 208 T cell clones showed cytotoxicity against primary CLL, CLL-APC and patient- derived targets and not against donor-derived EBV-LCL and

In summary, our study shows that T cell anergy to primary MCL cells can be reversed by transforming MCL cells into professional malignant APCs using CD40 ligation and provides

We have previously demonstrated that CLL-APC were immunogenic and capable of inducing mHag- specific and CLL-reactive T-cell responses in unprimed HLA-matched sibling